Terns soars as early data shows strong response in tough-to-treat leukemia

Terns Pharmaceuticals

03/11/2025 15:50

** Shares of drug developer Terns Pharmaceuticals TERN.O rise 82% to $15.07 during early trading

** Co says early-stage trial of experimental chronic myeloid leukemia drug, TERN-701, showed promising results

** TERN says 64% of chronic myeloid leukemia patients achieved major molecular response (MMR) by 24 weeks

** MMR means the level of leukemia in a patient's blood has dropped to a very low amount, showing that the treatment is effectively controlling the disease

** MMR rates were high even in patients who failed prior therapies like asciminib and ponatinib, co says

** Chronic myeloid leukemia is a type of blood cancer where the bone marrow makes too many abnormal white blood cells

** Including session's move, stock up ~171% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))